Shedding Light on Photobiomodulation Therapy for Age-Related Macular Degeneration: A Narrative Review.

ABSTRACT:

Background

Photobiomodulation (PBM) relies on the pathophysiological mechanism whereby red to near-infrared light can target mitochondrial activity and promote ATP synthesis. Preclinical and clinical studies have shown promising results in treating intermediate age-related macular degeneration (AMD), since PBM can produce photochemical reactions in endogenous retinal chromophores. Currently, PBM is approved by the Food and Drug Administration and by the European Medicines Agency for the treatment of intermediate AMD. This narrative review aimed to evaluate the available evidence on the effectiveness and safety of PBM in treating intermediate AMD.

Methods

A comprehensive search was conducted using the PubMed database, employing the keywords "photobiomodulation" and "age-relat

SUBMITTER: Fantaguzzi F 

PROVIDER: S-EPMC10640464 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature